North Rock Partners, LLC Cyclerion Therapeutics, Inc. Call Options Transaction History

North Rock Partners, LLC

  • $1.14 Billion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding CYCN

# of Institutions
1
Shares Held
293K
Call Options Held
0
Put Options Held
0
View Full List

About Cyclerion Therapeutics, Inc.

CYCN Quotes by TradingView
  • Ticker CYCN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,479,800
  • Market Cap $139M
  • Description
  • Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...
More about CYCN
Track This Portfolio

Track North Rock Partners, LLC Portfolio

Follow North Rock Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of North Rock Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on North Rock Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email